🆕: Higher DNA damage response in leukemic stem cells (CD34+CD38-CD26+) isolated from Ph+ #ChronicMyeloidLeukemia #BoneMarrow samples at diagnosis correlates with ⬇️probability to maintain durable TFR upon treatment discontinuation. Read the publication 👉bit.ly/3FmsTkv
Mel Mann: Gleevec’s Anniversary
Maj Mel Mann, Ret., MBA, M.Ed, Patient Advocate🎗️ TIME
oncodaily.com/63438.html
#Cancer #ChronicMyeloidLeukemia #Gleevec #OncoDaily #Oncology #Gleevec Survivor #CML
World Chronic Myeloid Leukemia (CML) Day
#WorldCMLDay #WorldCMLDay 2023 #CMLAwareness #ChronicMyeloidLeukemia #BloodCancer #CMLSupport #CMLResearch #CMLSurvivors #CMLAwareness Day #CancerAwareness #LeukemiaAwareness #CMLTreatment
drrajeshoncologist.com
Cepheid offers a wide range of tests, from specialized oncology to routine testing for critical infectious diseases and healthcare-acquired infections. Our goal is to provide the solutions you need to make a positive impact.
#oncologydiagnostic #Chronicmyeloidleukemia
World Chronic Myeloid Leukemia (CML) Day
#WorldCMLDay #WorldCMLDay 2023 #CMLAwareness #ChronicMyeloidLeukemia #BloodCancer
#CMLSupport #CMLResearch #CMLSurvivors #CMLAwareness Day #CancerAwareness
#LeukemiaAwareness #CMLTreatment
drbhanuoncologist.com
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
mediamedic.co/olverembatinib…
#ChronicMyeloidLeukemia #Olverembatinib
Chronic Myeloid Leukemia (CML) is a type of cancer that affects the blood and bone marrow. It is often asymptomatic in its early stages.
.
#ChronicMyeloidLeukemia #DrManoj #Treatmnent #Care #Oncologyst #Cancer #Cancer Care #Cancer symptoms
Xspray Pharma Settles With BMS Over Sprycel Generic, Awaits FDA Nod
Read More: pharmtales.com/xspray-bms-spr…
#pharmanews #pharmaupdates #Pharmtales #Leukemia #BristolMyersSquibb #ChronicMyeloidLeukemia #lawsuit #patent #Sprycel #Sprycel generic #XsprayPharma
bit.ly/EthanhasCML Not exactly a “traditional” holiday, but still one for somber observance. Thankfully there are brilliant scientists developing treatments that keep me alive and continuing to work toward a cure. #chronicmyeloidleukemia
#worldcancerday #cancelbloodcancer
External Validation of Predictive Scoring Systems for Molecular Responses in Chronic Myeloid Leukemia Receiving Imatinib Therapy mediamedic.co/external-valid…
linkedin.com/pulse/external…
#ChronicMyeloidLeukemia
#CML #hematologyresearch #Leukemiajournal
Imatinib compared with second-generation tyrosine kinase inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase
mediamedic.co/imatinib-compa…
linkedin.com/feed/update/ur…
#AmericanJournalofHematology #ChronicMyeloidLeukemia #CML
Discover our article on Challenges and Considerations for Conducting Phase II #ChronicMyeloidLeukemia (CML) #ClinicalTrials
Read more - bit.ly/3NNKXsv
To learn more about our Phase II Trial Solutions write to us at [email protected]
#Veeda #Leukemia #Phase2Trials
This World Chronic Myeloid Leukemia #WCMLD23 Day, let's honor the strength of those facing the 9-22 chromosome challenge. Together, we can rewrite the story of CML.
#WorldCMLDay
#wcmld23
#curecml
#cmlawarenessmonth
#Chronicmyeloidleukemia
#ChronicMyeloidLeukemia (CML) is a condition that demands our attention and compassion. Join us in casting a bright spotlight on CML at this year's World CML Day! The commemoration event will be held at The Nairobi Hospital on Saturday 23rd September from 10:00am.
#WorldCMLDay
New Arrival: Tyrosine Kinase Inhibitor-associated Cerebral Arterial Occlusive Disease Treated with High-flow Bypass Surgery: A Case Report
doi.org/10.2176/jns-nm…
#BypassSurgery #TyrosineKinaseInhibitor #Nilotinib #CerebralArteryDisease #Bcr_abl #ChronicMyeloidLeukemia
NEW in #ConferenceReporter : Hagop M. Kantarjian, MD, of MD Anderson Cancer Center reviews the current treatment landscape in #ChronicMyeloidLeukemia , noting updates from #ASH2022 .
expertperspectives.com/Conference%20R…
#onctwitter #oncology twitter #leukemia #oncology #hematology #ash22 ASH
NEW in #ConferenceReporter : Featured expert @mjamauroMD, reviews the current status of treatment-free remission in #ChronicMyeloidLeukemia , reviewing proceedings of #ASH2022 .
expertperspectives.com/Conference%20R…
#ASH22 #oncology #hemonc #medtwitter #twittermed #meded #mednews ASH
NEW in #ConferenceReporter : Neil P. Shah, MD, PhD of UCSF Helen Diller Family Comprehensive Cancer Ctr reviews newer developments in the treatment of patients with #ChronicMyeloidLeukemia receiving later lines of therapy, noting updates from #ASH2022 .
expertperspectives.com/Conference%20R…
ASH #ASH22 #oncology #hemonc
